STOCK TITAN

uniQure (NASDAQ: QURE) CLO granted options, RSUs and sells shares

Filing Impact
(Neutral)
Filing Sentiment
(Negative)
Form Type
4

Rhea-AI Filing Summary

uniQure N.V.’s Chief Legal Officer, Jeannette Potts, reported a mix of equity awards and an automatic share sale. She received a grant of 57,200 stock options with an exercise price of $0.00 per share and 35,400 restricted share units, each representing one ordinary share.

The restricted share units vest in three equal annual installments starting one year after the grant date, contingent on her continued service. The stock options vest 25% after one year and 6.25% quarterly thereafter. In connection with vesting, 3,412 ordinary shares were sold at a weighted average price of $9.06, within a $9.00–$9.22 range, solely to cover estimated withholding taxes under automatic sale instructions, and were not a discretionary trade.

Positive

  • None.

Negative

  • None.
SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Potts Jeannette

(Last) (First) (Middle)
C/O UNIQURE N.V.
PAASHEUVELWEG 25A

(Street)
AMSTERDAM P7 11058BP

(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
uniQure N.V. [ QURE ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director 10% Owner
X Officer (give title below) Other (specify below)
Chief Legal Officer
3. Date of Earliest Transaction (Month/Day/Year)
03/04/2026
4. If Amendment, Date of Original Filed (Month/Day/Year)
6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Ordinary Shares 03/04/2026 A 35,400(1) A $0 141,895 D
Ordinary Shares 03/04/2026 S(2) 3,412(2) D $9.06(3) 138,483 D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Stock Option (Right to Buy) $9.04 03/04/2026 A 57,200 (4) 03/04/2036 Ordinary Shares 57,200 $0 57,200 D
Explanation of Responses:
1. Represents restricted share units granted to the Reporting Person under the Issuer's 2014 Share Incentive Plan, as amended and restated. Each restricted share unit represents the contingent right to receive one Ordinary Share. The restricted share units vest in equal annual installments of 1/3 each, beginning on the first anniversary of the date of grant, subject to the Reporting Person's continued relationship with the Issuer through such dates.
2. The shares were sold upon the vesting of restricted share units solely to cover estimated withholding taxes, pursuant to automatic sale instructions included in the relevant Restricted Share Unit Agreement. The sale was not a discretionary trade by the Reporting Person.
3. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $9.00 to $9.22. The Reporting Person undertakes to provide to the Issuer, any shareholder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in the footnote.
4. The Stock Option vests 25% on the first anniversary of the date of grant, and 6.25% quarterly thereafter until fully vested, subject to the Reporting Person's continued relationship with the Issuer through such dates.
/s/ Christian Klemt, Attorney-in-Fact 03/06/2026
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transactions did uniQure (QURE) report for Jeannette Potts?

Jeannette Potts, uniQure’s Chief Legal Officer, received 57,200 stock options and 35,400 restricted share units, and reported an automatic sale of 3,412 ordinary shares used solely to cover estimated tax withholding obligations upon vesting of restricted share units.

How many uniQure (QURE) stock options were granted to the Chief Legal Officer?

The Chief Legal Officer received a grant of 57,200 stock options with an exercise price of $0.00 per share. These options vest 25% on the first anniversary of grant, then 6.25% quarterly until fully vested, subject to her continued relationship with uniQure.

What are the vesting terms of Jeannette Potts’ restricted share units at uniQure (QURE)?

Jeannette Potts was granted 35,400 restricted share units, each representing one ordinary share. These units vest in three equal annual installments of one-third each, starting on the first anniversary of the grant date, if she continues her relationship with uniQure.

Why did Jeannette Potts sell 3,412 uniQure (QURE) ordinary shares?

The 3,412 ordinary shares were sold automatically upon vesting of restricted share units solely to cover estimated withholding taxes. The sale followed pre-set automatic sale instructions and was not a discretionary trade by Jeannette Potts, according to the disclosure footnote.

At what price were Jeannette Potts’ uniQure (QURE) shares sold to cover taxes?

The 3,412 ordinary shares were sold at a weighted average price of $9.06 per share, with individual sale prices ranging from $9.00 to $9.22. The company states detailed trade breakdowns are available upon request from uniQure, shareholders, or SEC staff.

How many uniQure (QURE) ordinary shares does Jeannette Potts hold after these transactions?

After the reported transactions, Jeannette Potts directly holds 138,483 ordinary shares. This figure reflects the grant of 35,400 restricted share units and the automatic sale of 3,412 shares for tax withholding, as shown in the ownership totals provided.
Uniqure

NASDAQ:QURE

View QURE Stock Overview

QURE Rankings

QURE Latest News

QURE Latest SEC Filings

QURE Stock Data

888.90M
58.14M
Biotechnology
Pharmaceutical Preparations
Link
Netherlands
AMSTERDAM